Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.

Anxo Río-VilariñoAiora Cenigaonandia-CampilloAna García-BautistaPedro A Mateos-GómezMarina I SchlaepferLaura Del Puerto-NevadoOscar AguileraLaura García-GarcíaCarlos GaleanoIrene de MiguelJuana Serrano-LópezNatalia BañosMaría Jesús Fernández-AceñeroJuan Carlos LacalEnzo MedicoJesús García-FoncillasArancha Cebrián

Published in: British journal of cancer (2024)

AURKA inhibition holds promise as a therapeutic approach to overcome cetuximab resistance in RAS/RAF wild-type colorectal cancer, offering a potential means to counter the development of cancer stem cell phenotypes associated with cetuximab resistance.

Keyphrases

wild type
cancer stem cells
metastatic colorectal cancer
locally advanced
squamous cell carcinoma
big data
risk assessment
human health